Compare Gilead Sciences, Inc. (GILD) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs The Coca-Cola Co K — how do they compare? Gilead Sciences, Inc. trades at $133.19 (market cap $163.51B), while The Coca-Cola Co K trades at $84.28 (market cap $354.74B). The key difference: The Coca-Cola Co K is far larger — about 2.2× Gilead Sciences, Inc.'s market cap, and The Coca-Cola Co K pays the higher dividend (2.57%). Which is the better fit depends on your goals.
| GILD | KO | |
|---|---|---|
Market Cap | $163.51B | $354.74B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $84.25 |
52-Week Low | $108.22 | $65.67 |
Enterprise Value | $178.05B | $384.81B |
Dividend Yield | 2.49% | 2.57% |
Volume | — | 14,630,257 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Coca-Cola (KO) trades at $83.08, down 1.39% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $89.75. The company has beaten earnings expectations for three consecutive quarters, with Q1 2026 EPS of $0.86 exceeding the $0.812 estimate. Strong profitability metrics include a 27.8% net income margin and 45.8% ROE, though valuation ratios like a P/E of 25.93 and P/B of 10.55 appear elevated. Recent news highlights institutional buying and the company's 64-year dividend growth streak.
The outlook remains positive given consistent earnings beats, robust cash generation, and strong analyst support. Key opportunities include stable demand trends and dividend reliability, while risks involve premium valuation, regional volume divergence in Asia, and high debt levels. The stock presents a quality defensive holding with income appeal, though current multiples may limit near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
